NTNathan E. Thompson

Nathan E. Thompson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan E. Thompson has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antibiotic treatment duration for culture-negative sepsis in the pediatric intensive care unit

    by Kelsey Wehrenberg, Michelle Mitchell, Tracy Zembles, Ke Yan, Liyun Zhang, Nathan Thompson

    Objective:Sepsis remains a leading cause of morbidity and mortality in children. There is very limited guidance for sepsis treatment when cultures remain negative. This study sought to determine the effectiveness of short versus long course of antibiotics when treating culture-negative sepsis and assess for subsequent multidrug-resistant organism (MDRO) acquisition.Design:Retrospective cohort study.Setting:Quaternary academic children’s hospital.Patients:Pediatric intensive care unit (ICU) patients with culture-negative sepsis receiving a minimum of 72 hours of antibiotics.Methods:Patients found to have culture-negative sepsis from January 2017 to May 2020 were divided into two groups: short and long course of antibiotics. Various demographic and laboratory results were collected for each subject as available. Primary outcomes included mortality and lengths of stay. The secondary outcome was subsequent acquisition of a new MDRO.Results:Eighty-six patients were treated for culture-negative sepsis with 43 patients in both the short- (< or = 7 days) and long-course (>7 days) treatment cohorts. Patients who received a short course of antibiotics had a lower overall mortality than those who received a long course (9.3% vs 25.6% p = 0.047), but there was no difference in 30-day mortality (p > 0.99). Patients in the short-course group had a shorter hospital length of stay (22 vs 30 days p = 0.018). New MDROs were found in 10% of all patients.Conclusions:Treatment of culture-negative sepsis with short-course antibiotics was not associated with worse outcomes in ICU patients. These findings warrant further investigation with a larger, prospective, multi-center study.


  • DISTRIBUTION OF CARDIAC POWER INDICES FOLLOWING THE NORWOOD PROCEDURE

    by Stephanie Siehr Handler, Peter Frommelt, Rebecca A. Bertrandt, Robert Niebler, Nathan E. Thompson, John (Jake) Scott, Martin K. Wakeham, Adam Szadkowski, Francis Y. Kim, George Hoffman

  • Open Access

    Fluctuating asymmetry, a marker of poor growth quality, is associated with adult male metabolic rate

    by Daniel P. Longman, Sakura Oyama, James Cracknell, Nathan Thompson, Dan Gordon, Jay T. Stock, Jonathan C. K. Wells

    Objectives: Life history theory, a branch of evolutionary theory, predicts the existence of trade‐offs in energetic allocation between competing physiological functions. The core metabolic cost of self‐maintenance, measured by resting metabolic rate (RMR), represents a large component of human daily energy expenditure. Despite strong selective pressures for energetic frugality and high observed interindividual variation in RMR, the link between RMR and energetic allocation to life‐history traits remains understudied in humans.Materials: In a sample of 105 (m = 57, f = 48), we investigated the relationship between adult RMR and investment in growth quality, as measured by fluctuating asymmetry (FA).Results: Measurement of RMR and FA in university rowers revealed a significant positive correlation amongst males (n= 57,r= 0.344,p= 0.005, 1‐tailed; standardized 95% CI, 0.090 to 0.598). Convincing evidence for a correlation among females was not found (n= 48,r= 0.142,p= 0.169, 1‐tailed, standardized 95% CI, −0.152 to 0.435).Discussion: The data suggest that low‐quality asymmetrical growth is associated with later‐life metabolic inefficiencies in males. Energetic investment in processes (likely concerning the stress‐response) unrelated to growth during childhood may thereby trade‐off against adult metabolic efficiency. We suggest that the presence of a relationship between RMR and FA in males but not females may be explained by the additional metabolic strain associated with larger body size and increased male muscularity, which may amplify the inefficiencies arising from low‐quality growth.


  • Open Access

    Is Early Extubation Associated with Better Outcomes After Neonatal Congenital Heart Disease Surgery?

    by Nathan E. Thompson, Martin K. Wakeham

    Early extubation (EE) of children after surgery (occurring within the operating room or ≤ 6 hours postadmission) for congenital heart disease (CHD) has been advocated to improve postoperative care. The objective of this study is to compare outcomes of neonates undergoing EE following CHD surgical repair with those extubated more than 6 hours after surgery. Retrospective cohort study utilizes data from the Virtual Pediatric Systems database. Data from neonates undergoing surgical repair for six common CHD lesions and admitted to 57 pediatric intensive care units (ICUs) between July 1, 2010, and June 30, 2015, were analyzed. A total of 1,274 neonates were analyzed; 100 (7.8%) had EE, and 146 (11.5%) were extubated > 6 hours but ≤ 24 hours. Most patients (80.4%) were extubated > 24 hours. The EE group had higher (p < 0.001) failed extubation rate than patients extubated at any other time; a multivariate analysis of linear regression showed no advantage in length of stay (LOS) of EE compared with those subjects who were extubated in the first 24 hours (p-value: 0.178). Extubation failure was found to impact ICU LOS in this analysis. The ICU LOS was increased by 3.5 days for every failed extubation attempt (p-value: <0.001, 95% confidence interval: 1.6–5.5 days). EE after CHD surgery is possible. Though it appears as an attractive option to decrease potential mechanical ventilation complications, this study of neonates shows that EE might result in worse outcomes than when performing extubation between 6 and 24 hours postoperatively.


  • An Optimized Voriconazole Dosing Strategy to Achieve Therapeutic Serum Concentrations in Children Younger than 2 Years Old

    by Tracy N. Zembles, Nathan E. Thompson, Peter L. Havens, Bruce A. Kaufman, Anna R. Huppler

    Study Objective: To describe our experience with voriconazole in three patients younger than 2 years using an optimized dosing strategy for voriconazole that incorporates intensive therapeutic drug monitoring (TDM).Design: Case series.Setting: Large pediatric hospital.Patients: Three patients younger than 2 years who received voriconazole therapy and had serum trough concentrations measured between January 1, 2010, and October 31, 2015.Measurements and Main Results: A clinical practice guideline developed at our institution was used to standardize initial dosing, appropriate use and timing of TDM, and dosage modifications based on TDM. TDM was used to guide dosing to achieve a target voriconazole serum trough concentration of 2–6 μg/ml. Voriconazole samples were assayed by using a high‐performance liquid chromatography analytical method with solid‐phase extraction. Initial dosages for the three patients were 9 mg/kg intravenously every 12 hours (one patient) and 9 mg/kg enterally twice/day (two patients). Multiple dose escalations and a more frequent dosing interval were required to achieve trough concentrations within the target range. The final dosages were 12 mg/kg intravenously every 8 hours, 17.7 mg/kg enterally 3 times/day, and 8.5 mg/kg enterally 3 times/day, respectively. In addition to voriconazole trough concentrations, TDM included evaluations for drug toxicities. Visual, neurologic, or hepatic adverse effects were not encountered in the three patients.Conclusion: Our data support higher initial doses and perhaps a 3 times/day dosing schedule to achieve voriconazole serum concentrations in the target range for children younger than 2 years. Implementation of a clinical practice guideline with the participation of pharmacists specializing in pharmacokinetics allows for effective use of voriconazole in young children.